Recent cyber attack on London hospitals

All HSL-Advanced Diagnostic services remain unaffected and continue to operate normally. Read more...

Service Provision

The HSL-AD service is able to take in additional referral work to help maintain services under pressure. Please contact the laboratory if you are planning on referring a significant amount of additional work.

  Read more...

HSL Advanced Diagnostics Laboratory Move

We are pleased to inform you that from 30th March, 2020 HSL-Advanced Diagnostics will operate from our new and permanent location at 60 Whitfield Street Read more...

Advanced Diagnostics Validates New ROS1 IHC Assay for NSCLC

Following approval from NICE to allow access to Crizotonib for ROS1 positive patients with NSCLC, Advanced Diagnostics have made available a validated ROS1 IHC assay to all referring clients. Read more...

Advanced Diagnostics joins Health Services Laboratories pathology joint venture organisation

From the 1st May 2018 we are pleased to announce the creation of HSL Advanced Diagnostics. Read more...

Advanced Diagnostics are please to inform that we have received accreditation by UKAS to ISO15189:2012 standards

Advanced Diagnostics are please to inform that we have received accreditation by UKAS to ISO15189:2012 standards. Our UKAS customer number is 9007 and our scope of accreditation can be found here. Read more...

Advanced Diagnostics Accreditation Status

After a successful UKAS assessment on the 13th & 14th of December 2016, the Advanced Diagnostics laboratories are very happy to announce that we are currently "Recommended for Accreditation" to UKAS/ISO15189:2012 standards. Read more...

PD-L1 22C3 EAMS Reference Laboratory

HSL Advanced Diagnostics is now offering PD-L1 IHC testing using the Dako pharmDx 22C3 companion diagnostic for Pembrolizumab. Read more...

Advanced Diagnostics Validates New ALK IHC Assay for NSCLC

Advanced Diagnostics validates the new Roche Tissue Diagnostics ALK IHC assay for use in Non Small Cell Lung Cancer (NSCLC) patients for whom Crizotinib (Xalkori, Pfizer) is being considered. Read more...

Advanced Diagnostics Begins Centralised Testing for Major Clinical Trial.

Now open for recruitment, OPTIMA is a partially-blind randomised trial designed to compare clinical and economic outcomes of standard chemotherapy treatment with biomarker-directed allocation to chemotherapy or no chemotherapy in women with ER positive, HER2 negative breast cancer and either axillary node involvement or larger tumours'. Read more...

Advanced Diagnostics Attends Parliamentary Briefing on Targeted Cancer Diagnostics & Personalised Medicine

Representatives from Advanced Diagnostics/London Cancer & BCUK attend parliamentary briefing to discuss the importance of targeted testing and personalised medicine, with a specific focus on colorectal cancer, KRAS testing and Cetuximab. Read more...

Advanced Diagnostics Supports use of new Roche HER2 Teaching Resource

Roche unveil new HER2 teaching resource.  The 'HER2testing' web resource supports interpretation of HER2 testing in breast and gastric cancer in all areas including IHC, CISH, FISH and DDISH and provides a valuable resource for scientists and pathologists. Read more...

Advanced Diagnostics Adopts Roche Companion Diagnostics Testing Platform

Advanced Diagnostics has chosen to adopt Roche Pathway HER2 (4B5) on the Benchmark ULTRA automated staining system for use in breast and gastric cancer HER2 testing applications. Read more...